News - Medical and health professional investment - VC and PE investment business - Shenzhen Efung Investment Management Co. Ltd.

发布时间: 2025 - 09 - 22

Global First! Frontier Biotech's Dual-Target siRNA Drug FB7011 Brings New Treatment Option for IgA N

From September 17 to 20, 2025, the 18th International IgA Nephropathy Symposium (IIgANN 2025) was held in Prague, Czech Republic. At the conference, Frontier Biotech presented, for the first time as an oral report, the preclinical data for FB7011, a self-developed dual-target small nucleic acid drug with global first-in-class (FIC) potential. This drug simultaneously targets MASP-2, a key protein in the complement system's lectin pathway, and CFB, a key protein in the alternative pathway, blocking the pathogenesis of IgA nephropathy by precisely intervening in the abnormal activation of th...

浏览次数：2

查看详情>>

发布时间: 2025 - 09 - 19

IASO Biotherapeutics Releases Groundbreaking 3-Year Follow-Up Data for CAR-T Product Fucaso® in Mult

According to the study data based on enrollment, as of December 31, 2024, a total of 109 patients received treatment with Fucaso®. The median number of prior lines of therapy was 4. Among these patients, 12.8% had EMD, and 11% had received prior BCMA CAR-T therapy. After receiving lymphodepleting preconditioning with cyclophosphamide and fludarabine for three consecutive days, patients received a single infusion of CAR-T cells (1×10⁶ cells/kg).Among the 107 evaluable patients, the overall response (ORR) rate was 96.3%, with a complete response (CR) or stringent complete response (sCR...

浏览次数：1

查看详情>>

发布时间: 2025 - 09 - 16

Global Debut! Innova Pharma's YN001 Phase Ib/IIa Clinical Data Presented at ESC 2025 | Feng Investme

On September 1, at the European Society of Cardiology Congress 2025 (ESC Congress 2025) held in Madrid, Spain, the Phase Ib/IIa clinical trial data for YN001, the first innovative drug from Innova Pharma designed to reverse atherosclerotic plaques, was released globally for the first time. A clinical expert representative delivered an oral presentation titled "Active Targeted Liposomal Drug Significantly Reverses Atherosclerotic Plaques: A Proof-of-Concept Phase Ib/IIa Clinical Trial," reporting for the first time the remarkable efficacy and safety results from the YN001 Phase Ib/IIa...

浏览次数：2

查看详情>>

发布时间: 2025 - 09 - 12

The Only Anemia Treatment for Chronic Kidney Disease Supporting Weekly Oral Dosing Globally! First-i

On September 11, the official website of the Clinical Trial Registration and Information Platform showed that Andao Pharmaceuticals registered a Phase III clinical trial for oral AND017 capsules in subjects with anemia due to dialysis-dependent chronic kidney disease (DD-CKD). Public information indicates this is the first Phase III trial initiated for this drug.Screenshot source: Clinical Trial Registration and Information PlatformThis is a multicenter, randomized, open-label, active-controlled, parallel-group Phase III clinical trial designed to evaluate the efficacy and safety of AND017 in ...

浏览次数：1

查看详情>>